PL357259A1 - Pharmacological preparation - Google Patents

Pharmacological preparation

Info

Publication number
PL357259A1
PL357259A1 PL02357259A PL35725902A PL357259A1 PL 357259 A1 PL357259 A1 PL 357259A1 PL 02357259 A PL02357259 A PL 02357259A PL 35725902 A PL35725902 A PL 35725902A PL 357259 A1 PL357259 A1 PL 357259A1
Authority
PL
Poland
Prior art keywords
pharmacological preparation
cefuroxime axetil
lipids
lipid
insoluble
Prior art date
Application number
PL02357259A
Other languages
English (en)
Other versions
PL205325B1 (pl
Inventor
Matilde Ibanez Fernandez
Emilio Sanz Garriz
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PL357259A1 publication Critical patent/PL357259A1/xx
Publication of PL205325B1 publication Critical patent/PL205325B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Glanulating (AREA)

Abstract

Przedstawiono kompozycję zawierającą aksetyl cefuroksymu w rozdrobnionej postaci, cząstek pokrytych integralnymi powłokami lipidu lub mieszaniny lipidów, które są nierozpuszczalne w wodzie, a ponadto kompozycja zawiera układ słodzący i modyfikator tekstury, które służą do maskowania gorzkiego smaku aksetylu cefuroksymu przy podawaniu doustnym.
PL357259A 2001-11-23 2002-11-21 Kompozycja farmaceutyczna zawierająca aksetyl cefuroksymu PL205325B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01500277 2001-11-23

Publications (2)

Publication Number Publication Date
PL357259A1 true PL357259A1 (en) 2003-06-02
PL205325B1 PL205325B1 (pl) 2010-04-30

Family

ID=8183502

Family Applications (1)

Application Number Title Priority Date Filing Date
PL357259A PL205325B1 (pl) 2001-11-23 2002-11-21 Kompozycja farmaceutyczna zawierająca aksetyl cefuroksymu

Country Status (34)

Country Link
US (1) US20030161888A1 (pl)
EP (1) EP1446126B1 (pl)
JP (1) JP3497503B2 (pl)
KR (1) KR100979328B1 (pl)
CN (1) CN1297274C (pl)
AT (1) ATE473006T1 (pl)
AU (2) AU2002338950A1 (pl)
BE (2) BE1015217A5 (pl)
BR (1) BR0204767A (pl)
CA (1) CA2408198C (pl)
CH (1) CH693982A5 (pl)
CO (1) CO5580783A2 (pl)
CY (1) CY1110778T1 (pl)
CZ (1) CZ12993U1 (pl)
DE (3) DE20218068U1 (pl)
DK (1) DK1446126T3 (pl)
ES (2) ES2201932B2 (pl)
FR (1) FR2832635B1 (pl)
GB (1) GB2383536B (pl)
GR (1) GR1004522B (pl)
HR (2) HRP20020923A2 (pl)
HU (1) HUP0204026A3 (pl)
IL (2) IL161972A0 (pl)
IT (1) ITMI20022470A1 (pl)
MX (1) MXPA02011561A (pl)
NO (1) NO335273B1 (pl)
NZ (1) NZ533092A (pl)
PL (1) PL205325B1 (pl)
PT (1) PT1446126E (pl)
RU (1) RU2241460C2 (pl)
SI (1) SI1446126T1 (pl)
TR (1) TR200202559A2 (pl)
WO (1) WO2003043638A1 (pl)
ZA (1) ZA200209473B (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) * 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
ES2370729T3 (es) 2004-05-11 2011-12-22 Egalet Ltd. Forma farmacéutica hinchable que comprende goma gellan.
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
EP2417969A1 (en) 2004-10-21 2012-02-15 Aptalis Pharmatech, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
JP2012107060A (ja) * 2004-12-15 2012-06-07 Aska Pharmaceutical Co Ltd イソソルビドの苦味が軽減された経口製剤及びその製造方法
JP4972311B2 (ja) * 2004-12-15 2012-07-11 あすか製薬株式会社 イソソルビドの苦味が軽減された経口製剤及びその製造方法
DE102005019458A1 (de) 2005-04-25 2006-10-26 Grünenthal GmbH Darreichungsform mit verbesserter Freisetzung von Cefuroximaxetil
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
CN100402035C (zh) * 2005-07-07 2008-07-16 石药集团中奇制药技术（石家庄）有限公司 一种微囊化头孢呋辛酯的药物组合物
US8637076B2 (en) * 2006-06-01 2014-01-28 Cima Labs Inc. Prednisolone salt formulations
US20070281014A1 (en) * 2006-06-01 2007-12-06 Cima Labs, Inc. Prednisolone salt formulations
CN101756906B (zh) * 2009-11-02 2011-11-16 严洁 盐酸头孢卡品酯颗粒的药物组合物及其制备方法
NZ600256A (en) 2009-12-02 2014-05-30 Aptalis Pharma Ltd Fexofenadine microcapsules and compositions containing them
WO2011085181A1 (en) * 2010-01-08 2011-07-14 Eurand, Inc. Taste masked topiramate composition and an orally disintegrating tablet comprising the same
WO2011139254A2 (en) 2010-05-04 2011-11-10 Mahmut Bilgic Pharmaceutical formulations compising cefuroxime axetil
JP5853461B2 (ja) * 2010-07-30 2016-02-09 大正製薬株式会社 内服液剤
EP2741750A1 (en) 2011-08-12 2014-06-18 Dhanuka Laboratories Ltd. Pharmaceutical composition comprising cefuroxime
CN102440960A (zh) * 2011-09-01 2012-05-09 山东鲁抗医药股份有限公司 一种头孢呋辛酯干混悬剂药物组合物及其制备方法
EP2773204A4 (en) * 2011-10-31 2015-05-27 Glaxosmithkline Intellectual Property Ltd Pazopanib FORMULATION
CN108338936A (zh) * 2017-01-23 2018-07-31 刘全忠 敏感皮肤防护露的制备及使用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1323161A (en) * 1970-02-16 1973-07-11 Wyeth John & Brother Ltd Penicillin composition
GB1571683A (en) * 1976-02-16 1980-07-16 Glaxo Operations Ltd Ester derivatives of cefuroxime
CA1094545A (en) * 1976-02-16 1981-01-27 Michael Gregson Cephalosporin antibiotics
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
GB8320520D0 (en) * 1983-07-29 1983-09-01 Glaxo Group Ltd Chemical process
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
NL193682C (nl) * 1987-05-14 2000-07-04 Glaxo Group Ltd Beklede cefuroximaxetilsamenstelling.
US4992276A (en) * 1988-12-14 1991-02-12 Warner-Lambert Company Antiseptic compositions containing hexahydro-5-pyrimidinamine compounds and thymol and methods for preparing same
ES2194863T3 (es) * 1992-11-30 2003-12-01 Kv Pharm Co Materiales farmaceuticos con enmascarado de sabor.
IT1277426B1 (it) * 1995-08-03 1997-11-10 Acs Dobfar Spa Forma cristallina biodisponibile del cefuroxima axetil
NZ299077A (en) * 1996-07-26 1998-06-26 Apotex Inc Preparation of amorphous cefuroxime axetil (a cephalosporin derivative) by dissolving crystalline cefuroxim axetil in a highly polar solvent, typically dmso and/or dmf
PL191399B1 (pl) * 1996-10-28 2006-05-31 Gen Mills Inc Sposób kapsułkowania lub osadzania składnika w osnowie w procesie ciągłym, sposób kapsułkowania i/lub osadzania składników w osnowie opartej na węglowodanach, sposób kapsułkowania i/lub osadzania składników w osnowie oraz kapsułka
CA2209868C (en) * 1997-08-15 2001-08-14 Bernard Charles Sherman Pharmaceutical compositions comprising cefuroxime axetil
GB9726781D0 (en) * 1997-12-19 1998-02-18 Glaxo Group Ltd Pharmaceutical composition
AT413647B (de) * 1998-11-26 2006-04-15 Sandoz Ag Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten

Also Published As

Publication number Publication date
SI1446126T1 (sl) 2010-10-29
FR2832635B1 (fr) 2006-04-21
PL205325B1 (pl) 2010-04-30
CN1297274C (zh) 2007-01-31
ES2201932B2 (es) 2005-03-16
CA2408198A1 (en) 2003-02-02
GB2383536A (en) 2003-07-02
GB0227215D0 (en) 2002-12-24
HU0204026D0 (en) 2003-01-28
KR100979328B1 (ko) 2010-08-31
PT1446126E (pt) 2010-09-24
BE1015217A5 (pl) 2004-11-09
DE10254412A1 (de) 2003-06-12
ZA200209473B (en) 2003-06-10
KR20050044590A (ko) 2005-05-12
IL161972A (en) 2009-06-15
AU2002302147B2 (en) 2005-01-20
ATE473006T1 (de) 2010-07-15
RU2241460C2 (ru) 2004-12-10
MXPA02011561A (es) 2005-07-13
GR1004522B (el) 2004-04-06
CA2408198C (en) 2004-03-09
NO20042620L (no) 2004-06-22
HRP20020923A2 (en) 2003-10-31
HUP0204026A3 (en) 2004-09-28
JP3497503B2 (ja) 2004-02-16
ITMI20022470A1 (it) 2003-05-24
US20030161888A1 (en) 2003-08-28
JP2003160493A (ja) 2003-06-03
CO5580783A2 (es) 2005-11-30
NO335273B1 (no) 2014-11-03
GB2383536B (en) 2003-11-19
HUP0204026A2 (hu) 2003-08-28
NZ533092A (en) 2006-02-24
BR0204767A (pt) 2003-09-16
FR2832635A1 (fr) 2003-05-30
GR20020100506A (el) 2003-07-16
BE1014078A6 (fr) 2003-03-04
HRP20020924A2 (en) 2003-10-31
IL161972A0 (en) 2005-11-20
DK1446126T3 (da) 2010-10-11
DE20218068U1 (de) 2003-03-27
ES2201932A1 (es) 2004-03-16
CN1421206A (zh) 2003-06-04
CZ12993U1 (cs) 2003-02-10
CY1110778T1 (el) 2015-06-10
ES2347536T3 (es) 2010-11-02
WO2003043638A1 (en) 2003-05-30
AU2002338950A1 (en) 2003-06-10
CH693982A5 (de) 2004-05-28
TR200202559A2 (tr) 2003-06-23
EP1446126B1 (en) 2010-07-07
EP1446126A1 (en) 2004-08-18
DE60236952D1 (de) 2010-08-19

Similar Documents

Publication Publication Date Title
PL357259A1 (en) Pharmacological preparation
WO2006102446A3 (en) Multi-particulate, modified-released colonic composition
DE69313865D1 (de) Geschmacksmaskierende zusammensetzungen von ranitidin
MY103525A (en) Pharmaceutical composition comprising cefuroxime axetil
WO2000003742A3 (en) Solid oral dosage form comprising a combination of metformin and glibenclamide
DK1416842T3 (da) Farmaceutiske kombinationer af oxycodon og naloxon
CA2383355A1 (en) Vitamin b solution with reduced bitterness
WO2004071156A3 (en) Use of edible acid in fast-dispersing pharmaceutical solid dosage forms
AU2003256157A1 (en) Oral dosage forms of water insoluble drugs and methods of making the same
DE69813846D1 (de) Geschmacksmaskierung schlecht schmeckender formulierungen
WO2002019842A3 (de) Mittel mit verlängerter magenverweilzeit zur erzeugung eines langanhaltenden sättigungseffektes sowie dessen verwendung
DK0797997T3 (da) Anvendelse af peptidiske bradykinin-antagonister til fremstilling af lægemidler
DK1231890T3 (da) Oralt rensende produkt
HUP0301337A2 (hu) Terbinafint tartalmazó orális gyógyszerkészítmények és alkalmazásuk
AU2001235527A1 (en) Use of orally administered dehydroepiandrosterone, precursors and derivatives thereof in order to improve the papery aspect of the skin
TH12675S1 (th) ตะเกียง
TH46547S (th) ตะเกียง
TH42347S (th) เก้าอี้
TH47989S (th) หน้าฝักบัว
TH64132S (th) ผ้าอนามัย
TH26817S1 (th) ผ้าอนามัย
TH67210S (th) ผ้าอนามัย
AU2002303883A1 (en) Surface roughness quantification of pharmaceutical, herbal, nutritional dosage forms and cosmetic preparations
TH64846S (th) ผ้าอนามัย
TH18565S1 (th) ผ้าอนามัย

Legal Events

Date Code Title Description
RECP Rectifications of patent specification